Review





Similar Products

pd 1 pe  (Miltenyi Biotec)
94
Miltenyi Biotec pd 1 pe
Low-affinity CD5 CAR-T cells exhibit reduced fratricide and exhaustion phenotypes (A) Viability of CAR-T cells measured on day 3 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (B) Culture supernatants were collected on day 3 after cell seeding. IFN-γ and TNF-α levels secreted by CAR -T cells were measured by cytometric bead array. Data are presented as mean ± SD from multiple donors ( n = 3). (C) CD69 expression level of CAR-T cells on day 10 after seeding. Fluorescence intensity was quantified by flow cytometry. Data are presented as mean ± SD from multiple donors ( n = 3). (D) Total T cell number harvested on day 10 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (E) Expression levels <t>of</t> <t>PD-1</t> and LAG-3 (surface markers), and TOX (intracellular marker) in CAR-T cells on day 10 after seeding. Surface markers were analyzed by flow cytometry, and TOX expression was assessed via intracellular staining following fixation and permeabilization. Data are presented as mean ± SD from multiple donors ( n = 3). All statistical significance was assessed using a linear mixed-effects model with donor as a random effect and Tukey’s test.
Pd 1 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd 1 pe/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
pd 1 pe - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
anti human pd 1 antibody  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc anti human pd 1 antibody
a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of <t>PD-1–PD-L1</t> inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.
Anti Human Pd 1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human pd 1 antibody/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
anti human pd 1 antibody - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
fczero rabtm apc anti human pd  (Proteintech)
97
Proteintech fczero rabtm apc anti human pd
a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of <t>PD-1–PD-L1</t> inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.
Fczero Rabtm Apc Anti Human Pd, supplied by Proteintech, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fczero rabtm apc anti human pd/product/Proteintech
Average 97 stars, based on 1 article reviews
fczero rabtm apc anti human pd - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier
fczero rabtm apc anti human pd l1 cd274 rabbit recombinant antibody  (Proteintech)
98
Proteintech fczero rabtm apc anti human pd l1 cd274 rabbit recombinant antibody
a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of <t>PD-1–PD-L1</t> inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.
Fczero Rabtm Apc Anti Human Pd L1 Cd274 Rabbit Recombinant Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fczero rabtm apc anti human pd l1 cd274 rabbit recombinant antibody/product/Proteintech
Average 98 stars, based on 1 article reviews
fczero rabtm apc anti human pd l1 cd274 rabbit recombinant antibody - by Bioz Stars, 2026-04
98/100 stars
  Buy from Supplier
anti pd 1 pe vio770  (Miltenyi Biotec)
94
Miltenyi Biotec anti pd 1 pe vio770
a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of <t>PD-1–PD-L1</t> inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.
Anti Pd 1 Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pd 1 pe vio770/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti pd 1 pe vio770 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
pd 1 antibody  (Bio X Cell)
94
Bio X Cell pd 1 antibody
a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of <t>PD-1–PD-L1</t> inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.
Pd 1 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd 1 antibody/product/Bio X Cell
Average 94 stars, based on 1 article reviews
pd 1 antibody - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
anti human pd 1 antibody  (Bio X Cell)
95
Bio X Cell anti human pd 1 antibody
a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of <t>PD-1–PD-L1</t> inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.
Anti Human Pd 1 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human pd 1 antibody/product/Bio X Cell
Average 95 stars, based on 1 article reviews
anti human pd 1 antibody - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
invivomab anti human pd 1 antibody  (Bio X Cell)
93
Bio X Cell invivomab anti human pd 1 antibody
a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of <t>PD-1–PD-L1</t> inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.
Invivomab Anti Human Pd 1 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/invivomab anti human pd 1 antibody/product/Bio X Cell
Average 93 stars, based on 1 article reviews
invivomab anti human pd 1 antibody - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
mouse anti human anti pd 1 monoclonal antibody eh33  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc mouse anti human anti pd 1 monoclonal antibody eh33
a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of <t>PD-1–PD-L1</t> inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.
Mouse Anti Human Anti Pd 1 Monoclonal Antibody Eh33, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human anti pd 1 monoclonal antibody eh33/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
mouse anti human anti pd 1 monoclonal antibody eh33 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

Image Search Results


Low-affinity CD5 CAR-T cells exhibit reduced fratricide and exhaustion phenotypes (A) Viability of CAR-T cells measured on day 3 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (B) Culture supernatants were collected on day 3 after cell seeding. IFN-γ and TNF-α levels secreted by CAR -T cells were measured by cytometric bead array. Data are presented as mean ± SD from multiple donors ( n = 3). (C) CD69 expression level of CAR-T cells on day 10 after seeding. Fluorescence intensity was quantified by flow cytometry. Data are presented as mean ± SD from multiple donors ( n = 3). (D) Total T cell number harvested on day 10 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (E) Expression levels of PD-1 and LAG-3 (surface markers), and TOX (intracellular marker) in CAR-T cells on day 10 after seeding. Surface markers were analyzed by flow cytometry, and TOX expression was assessed via intracellular staining following fixation and permeabilization. Data are presented as mean ± SD from multiple donors ( n = 3). All statistical significance was assessed using a linear mixed-effects model with donor as a random effect and Tukey’s test.

Journal: Molecular Therapy Oncology

Article Title: Antigen-binding affinity is a key determinant of the durable antitumor activity of CD5 CAR-T cells

doi: 10.1016/j.omton.2026.201158

Figure Lengend Snippet: Low-affinity CD5 CAR-T cells exhibit reduced fratricide and exhaustion phenotypes (A) Viability of CAR-T cells measured on day 3 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (B) Culture supernatants were collected on day 3 after cell seeding. IFN-γ and TNF-α levels secreted by CAR -T cells were measured by cytometric bead array. Data are presented as mean ± SD from multiple donors ( n = 3). (C) CD69 expression level of CAR-T cells on day 10 after seeding. Fluorescence intensity was quantified by flow cytometry. Data are presented as mean ± SD from multiple donors ( n = 3). (D) Total T cell number harvested on day 10 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (E) Expression levels of PD-1 and LAG-3 (surface markers), and TOX (intracellular marker) in CAR-T cells on day 10 after seeding. Surface markers were analyzed by flow cytometry, and TOX expression was assessed via intracellular staining following fixation and permeabilization. Data are presented as mean ± SD from multiple donors ( n = 3). All statistical significance was assessed using a linear mixed-effects model with donor as a random effect and Tukey’s test.

Article Snippet: The following antibodies were used: BioLegend, CD5-PE (clone UCHT2), CD69-PE (clone FN50), LAG3-FITC (Clone 7H2C65), mIgG2a-AF647 (clone RMG2a-62), and streptavidin-AF647; BD Biosciences, CD4-V500 (clone RPA-T4), CD8-V450 (clone RPA-T8), αβ TCR-PE (clone IP26), and γδ TCR-BV421 (clone 11F2); Thermo Fisher Scientific, PD-1-PE (clone J105) and CD27-PE (clone O323); Miltenyi Biotec, TOX-APC (clone REA473), Vδ1-PE-Cy7 (clone REA173), and Vδ2-V500 (clone 123R3); Cell Signaling Technology, Myc-AF647 or PE (clone 9B11).

Techniques: Expressing, Fluorescence, Flow Cytometry, Marker, Staining

Affinity-tuned A2 variants provide functional evidence that antigen-binding affinity plays a key role in regulating fratricide and T cell exhaustion (A) Binding level of recombinant anti-CD5 scFvs to CD5-positive and CD5-negative cell lines, as measured by flow cytometry. Data are presented as mean ± SD from technical replicates ( n = 3). (B) Affinity properties of anti-CD5 scFvs as determined by biolayer interferometry using Octet system. A2 scFv was used as controls. (For definitions of K D , K a , K dis , and curve fit parameters, refer to legend.) (C) Viability of CAR-T cells measured on day 3 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (D) Culture supernatants were collected on day 3 to assess IFN-γ and TNF-α secretion, measured using cytometric bead array. Data are presented as mean ± SD from technical replicates ( n = 3). (E) Total T cell number harvested on day 10 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (F) CD69 expression levels in CAR-T cells on day 10 after cell seeding, measured by surface staining and flow cytometry. Data are presented as mean ± SD from multiple donors ( n = 3). (G) Expression levels of PD-1 and LAG-3 (surface markers) and TOX (intracellular) in CAR-T cells on day 10 after seeding. Surface markers were analyzed by flow cytometry, and TOX expression was assessed via intracellular staining. Data are presented as mean ± SD from multiple donors ( n = 3). (H) 3 × 10 5 Myc + CAR-T cells were co-cultured with 1 × 10 5 Jurkat cells every 3–4 days for repeated antigen stimulation. Expansion of Myc + CAR-T cells was measured weekly by flow cytometry. Data are presented as mean ± SD from technical replicates ( n = 3). Statistical analyses were performed using one-way ANOVA with Tukey’s multiple comparisons test for (A, D, and H) and a linear mixed-effects model with donor as a random effect followed by Tukey’s test for (C–G).

Journal: Molecular Therapy Oncology

Article Title: Antigen-binding affinity is a key determinant of the durable antitumor activity of CD5 CAR-T cells

doi: 10.1016/j.omton.2026.201158

Figure Lengend Snippet: Affinity-tuned A2 variants provide functional evidence that antigen-binding affinity plays a key role in regulating fratricide and T cell exhaustion (A) Binding level of recombinant anti-CD5 scFvs to CD5-positive and CD5-negative cell lines, as measured by flow cytometry. Data are presented as mean ± SD from technical replicates ( n = 3). (B) Affinity properties of anti-CD5 scFvs as determined by biolayer interferometry using Octet system. A2 scFv was used as controls. (For definitions of K D , K a , K dis , and curve fit parameters, refer to legend.) (C) Viability of CAR-T cells measured on day 3 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (D) Culture supernatants were collected on day 3 to assess IFN-γ and TNF-α secretion, measured using cytometric bead array. Data are presented as mean ± SD from technical replicates ( n = 3). (E) Total T cell number harvested on day 10 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (F) CD69 expression levels in CAR-T cells on day 10 after cell seeding, measured by surface staining and flow cytometry. Data are presented as mean ± SD from multiple donors ( n = 3). (G) Expression levels of PD-1 and LAG-3 (surface markers) and TOX (intracellular) in CAR-T cells on day 10 after seeding. Surface markers were analyzed by flow cytometry, and TOX expression was assessed via intracellular staining. Data are presented as mean ± SD from multiple donors ( n = 3). (H) 3 × 10 5 Myc + CAR-T cells were co-cultured with 1 × 10 5 Jurkat cells every 3–4 days for repeated antigen stimulation. Expansion of Myc + CAR-T cells was measured weekly by flow cytometry. Data are presented as mean ± SD from technical replicates ( n = 3). Statistical analyses were performed using one-way ANOVA with Tukey’s multiple comparisons test for (A, D, and H) and a linear mixed-effects model with donor as a random effect followed by Tukey’s test for (C–G).

Article Snippet: The following antibodies were used: BioLegend, CD5-PE (clone UCHT2), CD69-PE (clone FN50), LAG3-FITC (Clone 7H2C65), mIgG2a-AF647 (clone RMG2a-62), and streptavidin-AF647; BD Biosciences, CD4-V500 (clone RPA-T4), CD8-V450 (clone RPA-T8), αβ TCR-PE (clone IP26), and γδ TCR-BV421 (clone 11F2); Thermo Fisher Scientific, PD-1-PE (clone J105) and CD27-PE (clone O323); Miltenyi Biotec, TOX-APC (clone REA473), Vδ1-PE-Cy7 (clone REA173), and Vδ2-V500 (clone 123R3); Cell Signaling Technology, Myc-AF647 or PE (clone 9B11).

Techniques: Functional Assay, Binding Assay, Recombinant, Flow Cytometry, Expressing, Staining, Cell Culture

High-affinity C7 variant-based CAR5 exhibited increased levels of both fratricide and T cell exhaustion compared to the C7 wild-type CAR5 (A) Binding level recombinant anti-CD5 scFvs to CD5-positive and CD5-negative cell lines, as measured by flow cytometry. Data are presented as pooled mean ± SD from technical replicates ( n = 3). (B) Affinity properties of anti-CD5 scFvs as determined by biolayer interferometry using Octet system. C7 scFv was used as controls. (For definitions of K D , K a , K dis , and curve fit parameters, refer to legend.) (C) Viability of CAR-T cells measured on day 3 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (D) Culture supernatants were collected on day 3 to assess IFN-γ and TNF-α secretion, measured using cytometric bead array. Data are presented as mean ± SD from technical replicates ( n = 3). (E) Total T cell number harvested on day 10 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (F) CD69 expression levels in CAR-T cells on day 10 after cell seeding, measured by surface staining and flow cytometry. Data are presented as mean ± SD from multiple donors ( n = 3). (G) Expression levels of PD-1 and LAG-3 (surface markers) and TOX (intracellular) in CAR-T cells on day 10 after seeding. Surface markers were analyzed by flow cytometry, and TOX expression was assessed via intracellular staining. Data are presented as mean ± SD from multiple donors ( n = 3). (H) 3 × 10 5 Myc + CAR-T cells were co-cultured with 1 × 10 5 Jurkat cells every 3–4 days for repeated antigen stimulation. Expansion of Myc + CAR-T cells was measured weekly by flow cytometry. Data are presented as mean ± SD from technical replicates ( n = 3). Statistical analyses were performed using one-way ANOVA with Tukey’s multiple comparisons test for (A, D, and H) and a linear mixed-effects model with donor as a random effect followed by Tukey’s test for (C–G).

Journal: Molecular Therapy Oncology

Article Title: Antigen-binding affinity is a key determinant of the durable antitumor activity of CD5 CAR-T cells

doi: 10.1016/j.omton.2026.201158

Figure Lengend Snippet: High-affinity C7 variant-based CAR5 exhibited increased levels of both fratricide and T cell exhaustion compared to the C7 wild-type CAR5 (A) Binding level recombinant anti-CD5 scFvs to CD5-positive and CD5-negative cell lines, as measured by flow cytometry. Data are presented as pooled mean ± SD from technical replicates ( n = 3). (B) Affinity properties of anti-CD5 scFvs as determined by biolayer interferometry using Octet system. C7 scFv was used as controls. (For definitions of K D , K a , K dis , and curve fit parameters, refer to legend.) (C) Viability of CAR-T cells measured on day 3 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (D) Culture supernatants were collected on day 3 to assess IFN-γ and TNF-α secretion, measured using cytometric bead array. Data are presented as mean ± SD from technical replicates ( n = 3). (E) Total T cell number harvested on day 10 after cell seeding. Data are presented as mean ± SD from multiple donors ( n = 3). (F) CD69 expression levels in CAR-T cells on day 10 after cell seeding, measured by surface staining and flow cytometry. Data are presented as mean ± SD from multiple donors ( n = 3). (G) Expression levels of PD-1 and LAG-3 (surface markers) and TOX (intracellular) in CAR-T cells on day 10 after seeding. Surface markers were analyzed by flow cytometry, and TOX expression was assessed via intracellular staining. Data are presented as mean ± SD from multiple donors ( n = 3). (H) 3 × 10 5 Myc + CAR-T cells were co-cultured with 1 × 10 5 Jurkat cells every 3–4 days for repeated antigen stimulation. Expansion of Myc + CAR-T cells was measured weekly by flow cytometry. Data are presented as mean ± SD from technical replicates ( n = 3). Statistical analyses were performed using one-way ANOVA with Tukey’s multiple comparisons test for (A, D, and H) and a linear mixed-effects model with donor as a random effect followed by Tukey’s test for (C–G).

Article Snippet: The following antibodies were used: BioLegend, CD5-PE (clone UCHT2), CD69-PE (clone FN50), LAG3-FITC (Clone 7H2C65), mIgG2a-AF647 (clone RMG2a-62), and streptavidin-AF647; BD Biosciences, CD4-V500 (clone RPA-T4), CD8-V450 (clone RPA-T8), αβ TCR-PE (clone IP26), and γδ TCR-BV421 (clone 11F2); Thermo Fisher Scientific, PD-1-PE (clone J105) and CD27-PE (clone O323); Miltenyi Biotec, TOX-APC (clone REA473), Vδ1-PE-Cy7 (clone REA173), and Vδ2-V500 (clone 123R3); Cell Signaling Technology, Myc-AF647 or PE (clone 9B11).

Techniques: Variant Assay, Binding Assay, Recombinant, Flow Cytometry, Expressing, Staining, Cell Culture

a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of PD-1–PD-L1 inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.

Journal: bioRxiv

Article Title: Quantitative extrapolation from single-tags (QuEST) immunofluorescence microscopy to derive TCR signalosome stoichiometries in human primary T cells

doi: 10.64898/2026.03.28.715001

Figure Lengend Snippet: a – c , Workflow ( a ), representative TIRF images ( b ), and quantification results ( c ) of the number of signaling molecules per TCR following introduction of PD-1–PD-L1 inhibitory signaling in T cells. d , Stoichiometry of the TCR signalosome under PD-1–PD-L1 inhibitory signaling. e , Quantified sensitivity of signaling molecules within the TCR signalosome to PD-1–PD-L1 inhibitory signaling. f , Generation of T cells expressing low or high levels of PD-1. g , h , Representative TIRF images ( g ) and corresponding quantification results ( h ) of the number of signaling molecules per TCR in T cells expressing low or high levels of PD-1, with or without PD-1–PD-L1 inhibitory signaling. Data in f are presented as mean ± SD; data in c , d , and h are presented as mean ± SEM. In c , d , and h , ≥30 individual cells were analyzed per condition. Statistical significance was assessed using an unpaired two-tailed Student’s t -test (*** P ≤ 0.001). Data in c , d , and h are representative of two replicates using T cells from two blood donors. Data in f are representative of three replicates using T cells from three blood donors.

Article Snippet: Unlabelled primary antibodies : anti-human CD8α antibody (Cell Signaling Technology, Cat#85336), anti-human CD28 antibody (Cell Signaling Technology, Cat#38774S), anti-human CD45 antibody (Cell Signaling Technology, Cat#13917S), anti-human PD-1 antibody (Cell Signaling Technology, Cat#86163T), anti-human Lck antibody (Cell Signaling Technology, Cat#2787S), anti-human ZAP-70 antibody (Cell Signaling Technology, Cat#3165S), anti-human LAT antibody (Cell Signaling Technology, Cat#45533S), anti-human PLCγ1 antibody (Cell Signaling Technology, Cat#5690S), and anti-human phospho-ZAP-70 (Tyr319) antibody (Cell Signaling Technology, Cat#2701).

Techniques: Expressing, Two Tailed Test